SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 20 2025
0mins
Source: Newsfilter
Nirogacestat Approval Status: The European Medicine Agency's Committee has recommended the approval of nirogacestat for treating adults with progressing desmoid tumors, with a final decision from the European Commission expected in Q3 2025.
Clinical Trial Results: Nirogacestat showed significant improvements in progression-free survival and patient-reported outcomes in the Phase 3 DeFi trial, demonstrating its potential benefits for patients with no current treatment options in Europe.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
